FOS
( DrugBank: - / KEGG DRUG: - )
2 diseases
66. IgA腎症
臨床試験数 : 275 / 薬物数 : 258 - (DrugBank : 82) / 標的遺伝子数 : 36 - 標的パスウェイ数 : 140
Showing 1 to 5 of 5 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02433236 (ClinicalTrials.gov) | September 201520150900 | 29/4/201520150429 | Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy | A Phase 2, Multi-Centre, Open Label Extension Study of Fostamatinib in the Treatment of IgA Nephropathy for Patients Who Participated in Study C-935788-050 A Phase 2, Multi-Centre, Open Label Extension Study of Fostamatinib in the Treatment of IgA Nephropa ... | IGA Nephropathy | Drug: Fostamatinib Disodium tablet 100 mg;Drug: Fostamatinib Disodium tablet 150 mg | Rigel Pharmaceuticals | NULL | Withdrawn | 18 Years | 72 Years | Both | 0 | Phase 2 | NULL |
| 2 | NCT02112838 (ClinicalTrials.gov) | October 201420141000 | 10/4/201420140410 | Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy | A Phase 2, Multi-Center, Randomised, Double-Blind, Ascending-Dose, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of IgA Nephropathy A Phase 2, Multi-Center, Randomised, Double-Blind, Ascending-Dose, Placebo-Controlled Clinical Study ... | IGA Nephropathy | Drug: Fostamatinib 150 mg;Drug: Fostamatinib 100 mg;Drug: Placebo | Rigel Pharmaceuticals | NULL | Completed | 18 Years | 70 Years | All | 76 | Phase 2 | United States;Austria;Germany;Hong Kong;Taiwan;United Kingdom;Singapore;Switzerland |
| 3 | EUCTR2014-000331-16-AT (EUCTR) | 25/08/201420140825 | 22/07/201420140722 | N/A | A Phase 2, Multi-Center, Randomised, Double-Blind, Ascending-Dose, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of IgA Nephropathy - N/A A Phase 2, Multi-Center, Randomised, Double-Blind, Ascending-Dose, Placebo-Controlled Clinical Study ... | IgA nephropathy (IgAN);Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] | Product Name: Fostamatinib 100 mg tablet Product Code: R935788 INN or Proposed INN: Fostamatinib Other descriptive name: FOSTAMATINIB DISODIUM Product Name: Fostamatinib 150 mg tablet Product Code: R935788 INN or Proposed INN: Fostamatinib Other descriptive name: FOSTAMATINIB DISODIUM Product Name: Fostamatinib 100 mg tablet Product Code: R935788 INN or Proposed INN: Fostamatinib Other ... | Rigel Pharmaceuticals Inc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 75 | Phase 2 | United States;Hong Kong;Taiwan;Singapore;Austria;United Kingdom;Switzerland | ||
| 4 | EUCTR2014-000331-16-GB (EUCTR) | 28/07/201420140728 | 08/05/201420140508 | N/A | A Phase 2, Multi-Center, Randomised, Double-Blind, Ascending-Dose, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of IgA Nephropathy - N/A A Phase 2, Multi-Center, Randomised, Double-Blind, Ascending-Dose, Placebo-Controlled Clinical Study ... | IgA nephropathy (IgAN);Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] | Product Name: Fostamatinib 100 mg tablet Product Code: R935788 INN or Proposed INN: Fostamatinib Other descriptive name: FOSTAMATINIB DISODIUM Product Name: Fostamatinib 150 mg tablet Product Code: R935788 INN or Proposed INN: Fostamatinib Other descriptive name: FOSTAMATINIB DISODIUM Product Name: Fostamatinib 100 mg tablet Product Code: R935788 INN or Proposed INN: Fostamatinib Other ... | Rigel Pharmaceuticals Inc | NULL | Not Recruiting | Female: yes Male: yes | 92 | Phase 2 | United States;Hong Kong;Taiwan;Singapore;Austria;Switzerland;United Kingdom | ||
| 5 | NCT00318474 (ClinicalTrials.gov) | January 200220020100 | 24/4/200620060424 | Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy | A Randomized Controlled Trial of Mycophenolate Mofetil in Patients With IgA Nephropathy | IgA Nephropathy | Drug: Mycophenolate Mofetil (MMF);Drug: MMF Placebo;Drug: ACEi;Drug: FOS | St. Joseph's Hospital and Medical Center, Phoenix | NULL | Terminated | 7 Years | 70 Years | All | 184 | Phase 3 | United States |
96. クローン病
臨床試験数 : 2,442 / 薬物数 : 1,278 - (DrugBank : 248) / 標的遺伝子数 : 142 - 標的パスウェイ数 : 209
Showing 1 to 4 of 4 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-jRCTs031180415 (jRCTs031180415) | 01/02/201720170201 | 22/03/201920190322 | A trial of a combination therapy of fecal microbial transplantation and antibiotics for inflammatory bowel disease A trial of a combination therapy of fecal microbial transplantation and antibiotics for inflammatory ... | Single center non-randomized study: A trial of a combination therapy of fecal microbial transplantation and antibiotics for inflammatory bowel disease Single center non-randomized study: A trial of a combination therapy of fecal microbial transplantat ... | Inflammatory Bowel Disease (Ulcerative Colitis, Crohn's Disease) Inflammatory Bowel Disease (Ulcerative Colitis, Crohn's Disease) Inflammatory Bowel Disease (Ulcerative Colitis, Crohn's Disease) Inflammatory Bowel Disease (Ulcerat ... | AFM therapy arm : three antibiotics, amoxicillin (1500 mg/day), fosfomycin (3000 mg/day) and metronidazole (750 mg/day) are administered orally to patients for 2 weeks. For pediatric patients, amoxicillin (50mg/kg), fosfomycin (120mg/kg) and metronidazole (20mg/kg) are administered orally for 2 weeks (the upper limit is the same amount as adults). FMT arm : Approximately 150 to 250 g of donor stool is diluted with saline (500 mL) and filtered to remove crude components. The diluted and filtered fecal suspension is transferred into the patients colon from cecum to rectum during total colonoscopy. As usual examinations, the patient undergoes biopsy of inflammatory site. A-FMT arm : Patient undergoes FMT two days after AFM therapy. AFM therapy arm : three antibiotics, amoxicillin (1500 mg/day), fosfomycin (3000 mg/day) and metroni ... | Ishikawa Dai | NULL | Recruiting | >= 6age old | Not applicable | Both | 120 | N/A | Japan |
| 2 | JPRN-UMIN000025846 | 2017/02/0120170201 | 01/02/201720170201 | A trial of a combination therapy of fecal microbial transplantation and antibiotics for inflammatory bowel disease A trial of a combination therapy of fecal microbial transplantation and antibiotics for inflammatory ... | A trial of a combination therapy of fecal microbial transplantation and antibiotics for inflammatory bowel disease - A trial of a combination therapy of fecal microbial transplantation and antibiotics for inflammatory bowel disease A trial of a combination therapy of fecal microbial transplantation and antibiotics for inflammatory ... | ulcerative colitis, Crohn's disease | Administration of the fecal material from healthy donors to patients after taking three kinds of antibiotics (Amoxicillin, fosmycin, metronidazole) for two weeks Administration of the fecal material from healthy donors to patients after taking three kinds of ant ... | Juntendo university school of medicineDepartment of gastroenterology | NULL | Recruiting | 16years-old | Not applicable | Male and Female | 60 | Not selected | Japan |
| 3 | NCT02539849 (ClinicalTrials.gov) | December 201420141200 | 4/8/201520150804 | Effect of Prebiotic FOS on Intestinal Abundance of Faecalibacterium Prausnitzii in Patients With Crohn´s Disease Effect of Prebiotic FOSon Intestinal Abundance of Faecalibacterium Prausnitzii in Patients With Croh ... | Effect of Prebiotic Fructo-oligosaccharides (FOS) on Intestinal Abundance of Faecalibacterium Prausnitzii in Patients With Crohn´s Disease Effect of Prebiotic Fructo-oligosaccharides (FOS) on Intestinal Abundance of Faecalibacterium Prausn ... | Crohn Disease | Dietary Supplement: FOS;Drug: Adalimumab | Hospital Universitari Vall d'Hebron Research Institute | AbbVie | Completed | 18 Years | 65 Years | All | 38 | N/A | Spain |
| 4 | EUCTR2008-007329-38-ES (EUCTR) | 24/07/200920090724 | 24/04/200920090424 | Estudio multicéntrico, aleatorizado, con doble enmascaramiento en grupos paralelos, sobre la dexametasona intraeritrocitaria comparada con un placebo en pacientes con enfermedad de Crohn dependiente de esteroides - Intra-erythrocyte dexamethasone in patients with steroid-dependent Crohn?s Disease Estudio multicéntrico, aleatorizado, con doble enmascaramiento en grupos paralelos, sobre la dexamet ... | Estudio multicéntrico, aleatorizado, con doble enmascaramiento en grupos paralelos, sobre la dexametasona intraeritrocitaria comparada con un placebo en pacientes con enfermedad de Crohn dependiente de esteroides - Intra-erythrocyte dexamethasone in patients with steroid-dependent Crohn?s Disease Estudio multicéntrico, aleatorizado, con doble enmascaramiento en grupos paralelos, sobre la dexamet ... | Pacientes con enfermedad de Crohn dependiente de esteroides MedDRA version: 9.1;Level: LLT;Classification code 10011401;Term: Crohn's disease Pacientes con enfermedad de Crohn dependiente de esteroides MedDRA version: 9.1;Level: LLT;Classific ... | Product Name: dexamethasone sodium phosphate 250 mg/ 10 ml Product Code: ERY-DEX INN or Proposed INN: fosfato sodico de dexametasona Product Name: dexamethasone sodium phosphate 250 mg/ 10 ml Product Code: ERY-DEX INN or Proposed INN: ... | ERYDEL S.P.A. | NULL | Not Recruiting | Female: yes Male: yes | 184 | Spain;Italy |